E Canopy Growth Q3 Results Reveal Eye-Popping Net Loss Of $829M

Q3 Business & Operational Highlights

(All figures are compared to the previous quarter)

  • Further strengthened competitive positioning in the Canadian recreational market
    • Increased recreational cannabis market share by 30bps to 15.7%
      • Increased flower category market share by 180 bps
      • increased value flower category market share by 310bps to 16.8% 
    • Maintained beverage category market share at 34% in spite of new beverage brands entering the marketplace, retaining the top 3 brands
  • Built further momentum in the U.S. market
    • Increased distribution of its Martha Stewart health and wellness CBD products into 580+ Vitamin Shoppe and Super Supplements retail locations and is now outselling over 94% of all CBD brands in the U.S. in just 4 months since launch
    • Improved distribution and strong consumer pull ensured continued strong growth in its S&B vaporizer products
    • Strengthened direct (TW.com, shopcanopy.com) and third-party ecommerce sales channels.
  • Further streamlined operations and improved organizational focus
    • Ceased operations at a number of production facilities in Canada 
    • Divested its ownership in Canopy Rivers
    • Increased its direct conditional ownership of TerrAscend Corp.
    • Increased its ownership of Vert Mirabel greenhouse

Expected Medium-Term Financial Guidance

  • Net Revenue CAGR of 40%-50% from FY 2022 to FY 2024
  • Adjusted EBITDA to be positive during the second half of FY 2022
  • Adjusted EBITDA Margin of 20% for the full year FY 2024; and
  • Operating Cash Flow for the full year FY 2023 to be positive
  • Free Cash Flow to be positive for the full year FY 2024.

Key drivers underpinning the Company's financial targets include:

  • Growth of 40% in the Canadian legal recreational cannabis market growth in FY 2022 and market share gains;
  • Increase in CAGR of 25%-30% from FY 2022 to FY 2024;
  • Gains in market share in a stable-to-declining Canada medical cannabis market;
  • Growth in international medical cannabis driven by the German market;
  • Growth of the Company's U.S. CBD business, and consumer packaged goods business as a result of new product launches and distribution expansion in the U.S.;
  • Cost savings of $150M - $200M; and
  • Reduction in Capital Expenditures to below $200 million per year in FY 2021 and FY 2022.
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
William K. 1 month ago Member's comment

Was that an actual loss, or was $829m an estimate of the profit that should have been made, but instead was less than what was guessed?